Exhibitor List
0-9|A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|All
Keyword Search

Academia Sinica

Academia Sinica
National Biotechnology Research Park (NBRP)
Taiwan Biobank
Taiwan Mouse Clinic
National Core Facility for Biopharmaceuticals
Resident Companies of NBRP
Value-Added MedChem Innovation Center
Excelsior Biopharma Inc. / Excelsior Pharmatech Labs.
ALPS BIOTECH., LTD
Pharmaessentia Corp.

An Fam Enterprise Co., Ltd.

Opentrons OT-2 Liquid Handling platform, Thermocycler Module, Magnetic Module
MEGAROBO T4 4-axis robot arm

Bora Pharmaceuticals

Introduction of Bora Corp, and its division as well as products

CDC Development India Pvt Ltd.

TIIP is meant to be the pioneer industrial park for the High-End Technology, Electronics, EV, and Bio-tech companies to set up their manufacturing and R&D arms in this most advanced city of India, Bangalore.
State of art and Well equipped and comprehensive infrastructure will give the business investors the home coming atmosphere to settle their units within the park and start their operation in fast track.

Century Biotech Development Corporation

To enhanceand promote a world class biotech industry cluster in Taipei area,Taipei City Government aggressively promoted "Taipei NanKang Biotech Park" to provide a state of the art industrial space to host the development of new drugs and advanced medical devices. It is meant to bring the discovery of research in neighboring Academia Sinica, Taiwan national institute to preclinical study and extend to clinical study and pilotproduction of new drugs. This park is equipped with incubation center to provide the space to host new startups and well planned infrastructure for well-built biotech companies to accommodate their requirements for laboratory, office and pilot production spaces.
With its outstanding location for transportation, next to Nangkang Station, Taipei NanKang Biotech Park will enrich the portfolio of Taipei hi-tech Industrial clusters and itself becomes one of the landmarks of Taipei East District Gateway Project.

Development Center for Biotechnolgoy

Development Center for Biotechnology (DCB) is founded in 1984 and has its mission to facilitate the ongoing growth and development of Taiwan's biotech industry. To this end, we strive to act as the industry's partner, coordinating resources among government, academia and private companies. DCB plays a key role in building and upgrading Taiwan's biomedical infrastructure, developing critical technologies and culturing Taiwan's professional workforce, and also contually fosters international partnerships and collaborations with research institutes and global biopharmaceuticals throughout Asia and the world.
In both fields of small molecules and biologics, we may provide plenty of drug development services as well as new drug candidates for out-licensing, which are in the preclinical stage, and platforms which can be adopted in your design of drugs.
Info of said candidates for out-licensing, please refer to:
DCB:https://www.dcb.org.tw/
DCB Technology promotion:https://www.dcb.org.tw/posts/729
www.dcb.org.tw/pages/12
www.dcb.org.tw/technologies
https://www.dcb.org.tw/posts/729
Cooperation projects and needs
1. Process development for T-cell & CAR-T therapy: Looking for licensee or clinical partners.
2. iPSC & MSC: Looking for clinical partners for the development of various applications; academic/commercial R&D members who have demands on iPSC.
3. Medical Image AI: Looking for clinical partners for the development of various applications; licensee, business partners or investors.

EirGenix, Inc.

EirGenix has core capacity in R&D and manufacturing, producing biologics compliant with PIC/S GMP, and has 7 products undergoing development. EirGenix has two main business units:

1.Contract Development & Manufacturing Operation Unit:
EirGenix produces microbial and mammalian cell based biologics compliant with PIC/S GMP from cell line development to drug substance, and provides process development and quality control (QC) analysis for products.

Cell Line Development & Cell Banking Service:
Contract Development & Manufacturing Service:
Analytical Science & QC analysis Service:
Antibody Drug Conjugate (ADC) service: Partnering with Formosa Laboratories, Ltd.

2.Product Development & Operations Unit:
EirGenix currently has seven biologics undergoing development.

EG12014/EGI014 (Trastuzumab Biosimilar) treats HER2 gene variance cancer. It received approval from US FDA, Taiwan FDA, EMA...etc and began phase III clinical trial.
EG1206A (Pertuzumab Biosimilar) treats HER2 gene variance cancer.
EG13074 (New Formulation) treats HER2 gene variance cancer.
TSY0110(EG12043) (Antibody-Drug Conjugate) treats HER2 gene variance cancer.
EG12021 (Bevacizumab Biosimilar) inhibits cancer by anti-angiogenesis.
EG74032 (CRM197 Carrier Protein) can be used for vaccination.
EG62054 (Biosimilar)
Cooperation projects and needs
1. Provide Cell Line Development, Manufacturing Process Development , and Analytical Service
2. Provide PIC/S GMP Manufacturing Service of biologics including recombinant protein, fusion protein, plasmid, monoclonal antibody, biosimilar etc.
3. Provide Analytical Science & QC analysis Service

GlaxoSmithKline Far East B. V. Taiwan Branch

GSK is science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Our goal is to be one of the world's most innovative, best performing and trusted healthcare companies. In this exhibition, we will be showcasing our innovations in healthcare and the work we do in Taiwan.

Golden Biotechnology Corp.

Golden Biotechnology Corp.,leading pharma in cancer and other new drugs . Received Orphan Drug Designations by US FDA for Pancreatic Cancer, AML and HCC and Pancreatic Cancer by EU EMA. Completed first stage of Phase II trial of NSCLC and released in 2019 ASCO meeting.Winner of the Advance Queensland - Johnson & Johnson Innovation QuickFire Challenge in Alzheimer's Disease study in 2016. In 2018 , successful unblinding on clinical trial of hyperlipidemia. Welcome visit us at Booth S931 Biotech &Pharmaceuticals Area.
1. Golden Biotechnology Corp.'s latest developments and clinical progress of new drug Antroquinonol® in Non-small Cell Lung Cancer(NSCLC), Pancreatic Cancer, Liver Cancer(HCC), Hyperlipidemia, Atopic Dermatitis, Hepatitis B, Alzheimer's disease, Non alcoholic Steatohepatitis(NASH) and AML.
2. EBH(EvidenceBase Healthy)

HCT Regenerative Co., Ltd.

HCT Regenerative is an American Association of Tissue Banks (AATB) accredited biomedical company. It is the only Taiwanese biomedical company specialized in biologics, regenerative biomaterials, medial devices based on human tissue. HCT Regenerative is the only AATB accredited company that manufactures amnion related products in Asia.
Cooperation projects and needs
1. Looking for tissue product distributors from other asian markets.
2. Looking for mid/small size device companies to co-develop medical devices, biologics, such as DBM putty, amniotic fluids.